Mochida Debuts Japanese Teriparatide Biosimilar

Biosimilar Of Eli Lilly’s Forteo Hits Japanese Market

Mochida has launched the first Japanese teriparatide biosimilar rival to Eli Lilly’s blockbuster osteoporosis drug Forteo. The company is hoping for big sales for the injectable in the country where the government is aiming to rein in healthcare costs for its rapidly ageing population.

Paper boats
Mochida is leading the way on Japanese teriparatide • Source: Shutterstock

Mochida Pharmaceutical has announced the launch of the first biosimilar in Japan of Eli Lilly’s blockbuster osteoporosis drug Forteo (teriparatide). The company hopes to clock significant sales from the biosimilar in Japan, where life expectancy is among the longest in the world and rates of osteoporosis are increasing.

The Mochida product is also the first biosimilar to go on sale in Japan’s osteoporosis market. Mochida said it developed...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.